Ardenn BioSystems is an early-stage diagnostics startup developing biomarker-based methods for understanding human neurological and cognitive performance.
Register interest in research updatesOur flagship development focuses on detecting Phosphoglycerate Kinase 1 (PGK1) biomarkers in saliva to assess cognitive fatigue in real-time. This non-invasive approach offers a practical solution for monitoring mental acuity in demanding professional settings.
Ardenn BioSystems is an early-stage biotechnology company. Our technologies are currently in research and development. Preliminary clinical validation studies have been completed, and regulatory pathways are currently being assessed.
If you are a researcher, clinician, institutional partner, or investor interested in Ardenn's work, you may register your interest below.
This is not a product waitlist. Registration does not guarantee access to any future product or service. We use this registry to inform relevant parties of research progress, partnership opportunities, and institutional updates.